Drugs / PF-05180999
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01981486 | Jun 2014 → Jan 2015 | migraine disorder | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT01981499 | Jan → Apr 2014 | migraine disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01530529 | Jan → Apr 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01429740 | Aug → Dec 2011 | schizophrenia | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05180999 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01981499 ↗ |
| Known as | PF-999 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3092562 ↗ |
| Action | Inhibit | “PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor.” NCT01981486 ↗ |
| Modality | Small molecule | — CHEMBL3092562 ↗ |
| Route | Oral | “Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules” NCT01429740 ↗ |